Novo Nordisk, Eli Lilly fall after Trump comments on weight loss drug pricing
Mark Sullivan, Chief Legal Officer of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), sold 11,278 common shares of the company on September 25, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The transaction comes as MindMed’s stock trades near its 52-week high of $11.02, having delivered an impressive 48.48% return over the past six months.
The shares were sold at a price of $9.77, for a total transaction value of $110,186. The filing indicates the sale was to cover withholding tax obligations related to the settlement of vested restricted stock units, executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 14, 2024.
In other recent news, Mind Medicine Inc reported its second-quarter earnings for 2025, focusing on its financial health and future prospects. The company disclosed a strong cash position, with a cash runway extending into 2027, underscoring its ability to sustain operations and continue investing in research and development. Mind Medicine’s earnings per share (EPS) was reported at -$0.50, which fell short of the analyst forecast of -$0.37 by 35.14%. Despite missing the earnings estimate, the company’s stock saw a positive reaction in aftermarket trading, indicating investor confidence in its long-term strategy. These developments highlight the market’s interest in Mind Medicine’s pipeline and strategic direction.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.